When does Ozempic’s NCE (new chemical entity) exclusivity expire?
Ozempic (semaglutide) received FDA approval that granted new chemical entity (NCE) exclusivity of 5 years from the product’s approval date, which limits certain generic entry during that window. The exact expiration date depends on the specific FDA approval date for Ozempic.
What does NCE exclusivity restrict, and how is it different from patent protection?
NCE exclusivity is an FDA exclusivity right tied to approval of the “new active ingredient.” It can block approval of some generic competitors even if they file an ANDA, but it is separate from patents that can extend market protection longer through patent infringement litigation.
How can generic or competing “semaglutide” products still come before NCE exclusivity ends?
Even with NCE exclusivity in place, some competitors may be able to enter if they rely on approval pathways that are not barred by that exclusivity, or if they target different claims and formulations. Patent listings and Orange Book protections can still be the deciding factor for timing in many cases.
Is there a DrugPatentWatch.com page that lists Ozempic exclusivity/patent timing?
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs and is often used to estimate when exclusivity and key patents end. If you share the FDA approval date you’re using (or whether you mean Ozempic 0.25/0.5 mg, 1 mg, 2 mg, or another strength/label), I can map that to the 5-year NCE window and provide the exact expiration date using that reference.
Sources (not provided in your prompt):
Please provide the Ozempic FDA approval date or any link/text you’re working from, and I’ll calculate the NCE expiration precisely and cite the relevant timeline (including, where appropriate, DrugPatentWatch.com).